Neuland Laboratories (NSE:NEULANDLAB) ROCE %: 53.10% (As of Mar. 2026)


NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
90 GF Score
Price ₹17,961.00
GF Value ₹16,462.93
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Neuland Laboratories ROCE %?

Neuland Laboratories NSE:NEULANDLAB -0.61% 90 ROCE % is 53.10% as of Mar. 2026. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,462.93 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neuland Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 53.10%.

Neuland Laboratories  (NSE:NEULANDLAB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neuland Laboratories ROCE % Related Terms

Neuland Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories ROCE % Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.28 20.93 32.41 22.74 26.08

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.72 5.17 28.53 12.97 53.10
NSE:NEULANDLAB
90GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories ROCE % Calculation

Neuland Laboratories's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=5129.245/( ( (21798.816 - 4656.859) + (29301.377 - 7101.98) )/ 2 )
=5129.245/( (17141.957+22199.397)/ 2 )
=5129.245/19670.677
=26.08 %

Neuland Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=11787.996/( ( (0 - 0) + (29301.377 - 7101.98) )/ 1 )
=11787.996/( ( 0 + 22199.397 )/ 1 )
=11787.996/22199.397
=53.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 53.10% mean?
Neuland Laboratories (NSE:NEULANDLAB) has a ROCE % of 53.10% as of Mar. 2026.
Is Neuland Laboratories' ROCE % too high?
Neuland Laboratories' current ROCE % is 53.10%. The Drug Manufacturers industry median ROCE % is 7.00. Neuland Laboratories' value of 53.10% is 659.1% above this industry median. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' ROCE % compare to ZTS?
Neuland Laboratories' ROCE % of 53.10% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Neuland Laboratories' value of 53.10% is 659.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current ROCE % of 53.10% is 659.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current ROCE % is 53.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,462.93, compared to a current price of ₹17,961.00 — trading 9.1% above its estimated fair value. The current ROCE % is 53.10% and 659.1% above the Drug Manufacturers industry median of 7.00. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current ROCE % is 53.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹17,961.00 is trading 9.1% above its estimated GF Value™ of ₹16,462.93. GuruFocus considers Neuland Laboratories to be Fairly Valued.

Key valuation signals for NSE:NEULANDLAB:

  • ROCE %: 53.10%
  • GF Value™: ₹16,462.93 vs. price of ₹17,961.00 (9.1% above fair value)
  • GF Score™: 90/100 with 2 warning signs
  • Industry Position: 659.1% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score

Get the complete analysis for NSE:NEULANDLAB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17,961.00
Price
₹16,462.93
GF Value